CNS Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2020. CNS is a clinical-stage pharmaceutical company developing anti-cancer drug candidates, with Berubicin as its lead program. The interim financial statements are unaudited.
Financial performance and position
- Revenue: No revenue is reported; the filing presents the company as a clinical-stage developer.
- Net loss: $2.011 million for Q3 2020 versus $0.707 million in Q3 2019; $6.453 million for the first nine months of 2020 versus $1.350 million in the comparable 2019 period.
- Operating expenses: Q3 2020 expenses were $2.011 million, including $0.969 million general and administrative and $1.042 million research and development. Nine-month expenses were $6.453 million, including $3.305 million general and administrative and $3.148 million research and development.
- Cash flow: Operating cash use was $5.871 million for the first nine months of 2020, compared with $1.078 million in 2019. Investing cash use was $18,000; financing cash use was $45,000. Cash declined by $5.934 million to $1.307 million.
- Liquidity: At September 30, 2020, current assets were $2.516 million, current liabilities $0.511 million, and reported working capital approximately $2.005 million. Management said cash could fund planned operations into, but not beyond, the near term.
- Debt and equity: The balance sheet reports no debt; total liabilities were $0.511 million. Stockholders’ equity was $2.474 million, down from $7.601 million at December 31, 2019. The company had 16,652,225 common shares outstanding at September 30.
- Margins: Not applicable because the filing reports no revenue.
Changes versus the prior comparable period
- Q3 net loss increased by approximately $1.304 million year over year; nine-month net loss increased by approximately $5.103 million.
- Nine-month general and administrative expense rose to $3.305 million from $0.893 million, and research and development expense increased to $3.148 million from $0.417 million. Management attributed the increases primarily to expanded operations following the November 2019 IPO, including clinical-trial preparation, personnel, stock compensation, professional fees, marketing, and insurance.
- Operating cash use increased to $5.871 million from $1.078 million, while cash fell from $7.241 million at year-end 2019 to $1.307 million.
Outlook, risks, and notable items
- Management estimated it would need an additional $30–$35 million to complete the redesigned Berubicin Phase II trial, approximately $2 million for near-term WP1244 preclinical work, and additional working capital. The estimates are subject to uncertainty; the filing gives no assurance of financing or trial outcomes.
- The company disclosed substantial doubt about its ability to continue as a going concern, citing recurring losses and operating cash outflows and dependence on additional financing.
- A September 2020 agreement gives Lincoln Park the option to purchase up to $15 million of common stock over 36 months, subject to conditions and purchase limits. It is a potential funding source, not cash already raised; the company issued 201,991 commitment shares. Future sales could dilute shareholders and pressure the stock price.
- The company is preparing Berubicin clinical development and expects R&D costs to rise as development expands. The FDA granted Berubicin Orphan Drug Designation in June 2020; the filing describes potential U.S. exclusivity after approval, subject to exceptions.
- The company reported that the SEC temporarily suspended trading in May 2020 following statements concerning WP1122 and COVID-19; Nasdaq also halted trading pending additional information. Both halts were later lifted. The company warned similar actions could recur.
- Management concluded disclosure controls were ineffective because of a material weakness in internal control over financial reporting related to insufficient personnel for segregation of duties. It described additional review procedures and plans to add experienced staff, retain consultants, and upgrade its accounting system when feasible.
- Related-party arrangements include the WP1244 sponsored research agreement with UTMDACC, whose principal investigator is the company’s founder and majority controller, and agreements involving founder-affiliated WPD and HPI. The company committed approximately $1.134 million over two years for UTMDACC research and accrued $200,000 at quarter-end.
Facts investors should verify
- Available cash, actual monthly cash burn, and the timing and terms of additional financing.
- Whether the Lincoln Park facility’s registration and other conditions are satisfied, how much is drawn, and the resulting dilution.
- Berubicin Phase II trial design, funding needs, regulatory path, and development milestones.
- Progress and spending under the WP1244 license and sponsored research commitments, including related-party terms.
- Remediation of the material weakness and any subsequent changes in disclosure controls.
- Any further SEC or exchange actions concerning the company’s disclosures or trading.